PRAGUE, LONDON and CHICAGO, Sept. 11, 2025 — Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR.

Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to successfully transform the business, whilst investing to expand Zentiva’s portfolio of medicines and manufacturing footprint, both organically and through targeted M&A. This transformation programme has built Zentiva into a highly successful standalone business, with a strong focus on operational excellence and R&D capabilities, serving millions of patients across Europe.

GTCR is a leading private equity firm with a long history of investments in the healthcare sector and deep domain expertise in the pharmaceutical industry specifically, having invested behind several leading platforms and completed dozens of acquisitions in the space in the last 20 years. With GTCR’s track record in the pharmaceutical space and its focus on partnering with management teams to build market-leading companies through organic growth, product innovation and strategic acquisitions, it is well-positioned to support Zentiva in this next phase of growth.

Steffen Saltofte, CEO, Zentiva, said, “Advent has been an exceptional partner in Zentiva’s transformation journey. Their commitment to investing in our capabilities, pipeline, and manufacturing base has been instrumental in our growth and in ensuring we can better serve millions of patients across Europe. As we move forward with GTCR, we are excited to build on this momentum to ensure continued growth and expand access to high-quality, affordable medicines.”

Tom Allen, Managing Director at Advent, said, “When we acquired Zentiva from Sanofi in 2018, we saw the opportunity to build an independent European leader in affordable medicines. By actively working with the management team and investing in the company’s capabilities, Zentiva has more than doubled its revenue and EBITDA, establishing a strong foundation for the future. Zentiva exemplifies Advent’s ability to carve out and transform non-core divisions into thriving, market-leading businesses. We are proud of what has been achieved and confident Zentiva will continue to excel under GTCR’s ownership.”

Sean Cunningham, Managing Director and Head of Healthcare at GTCR, said, “We are delighted to partner with Steffen Saltofte and the talented Zentiva management team for its next phase of growth. The Company has an impressive track record of organic and inorganic expansion, a strong pipeline, and a highly efficient manufacturing platform, with a critical focus on delivering high-value medicines to patients across Europe. We look forward to supporting Zentiva as it continues to deliver on its mission.”

The transaction is subject to customary regulatory approvals and its closing is expected to take place in early 2026.

Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors and Freshfields as lead legal advisor.

GTCR was advised by Barclays Bank PLC, acting through its Investment Bank, and BNP Paribas as lead financial advisors, Morgan Stanley & Co. LLC as a financial advisor, and Kirkland & Ellis LLP as legal advisor.

About Zentiva

Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,000 unique talents, bonded together by a commitment to the people who depend on our medicines every day.  Visit us at www.zentiva.com. 

About Advent

Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $100 billion in assets under management* and have made 435 investments across 44 countries.

Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.

As one of the largest privately-owned partnerships, our 675+ colleagues leverage the full ecosystem of Advent’s global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.

To learn more, visit our website or connect with us on LinkedIn.

*Assets under management (AUM) as of June 30, 2025. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles

About GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in over 290 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com.

Logo – https://mma.prnewswire.com/media/2660891/5411039/Zentiva_Logo.jpg

SOURCE Zentiva

The funding will support Quack’s expansion and product innovation to reimagine customer support as a holistic operating system that solves CX issues before they arise.

SAN FRANCISCO, Sept. 11, 2025 — Quack, the proactive agentic AI platform for customer support, today announced it has raised $7 million in seed funding led by Hanaco Ventures, and Storytime Capital, with participation from Fusion VC, Savyon Ventures, Seed IL, and private investors including WalkMe CEO Dan Adika. The new capital will accelerate Quack’s US go-to-market strategy and product innovation as the company further advances its operating system for training and managing proactive AI agents.

For B2B, B2C, D2C and SaaS companies, scaling customer support remains one of the most challenging obstacles to sustainable growth. Building quality in-house support systems is costly and slow, while existing chatbot and flow builder solutions are generic, reactive, and unable to handle complex tickets and infinite use cases. As a result, customer support teams are overwhelmed, help centers are outdated, and end users are frustrated. Agentic AI will be able to resolve 80% of common customer support issues by 2029, reducing operational costs by at least 30%. Yet with the number of frustrated users outpacing the number who open support tickets, the vast majority of CX issues are left unreported while customers churn. Quack addresses these critical challenges by enabling them to deploy a network of AI agents that proactively resolve issues even before they escalate to CX teams, allowing them to do more with less. By transforming support from a cost center into a growth driver, Quack empowers SaaS companies to scale without compromising customer experience.

Quack is the only proactive AI agent platform that seamlessly integrates with any CRM. Purpose-built for SaaS and high-growth companies, Quack enables customer support teams to train, deploy, and manage an unlimited number of AI agents across channels, with extremely fast time to value. Quack’s intuitive topic-by-topic training of its AI mirrors the process of training a human agent, building deep, contextual knowledge tailored to the complexity of a SaaS company. This approach allows human support team members to act as product experts, focusing on sophisticated, high-touch issues where expertise matters most. Quack also provides robust quality assurance capabilities that span all human and AI interactions, ensuring reliability and continuously improving performance by feeding back into the AI. With seamless, efficient, and intelligent support at scale, Quack is redefining CX.

“Proactivity is the future of customer support. We’re deeply grateful to our investors, who recognize the scale of the challenge and the opportunity behind the Quack vision,” said Nadav Kemper, CEO of Quack. “Customer support has been stuck in reactive mode for too long; it is costly to run, painful to scale, and a frustrating experience for customers. At Quack, we believe support should be proactive, agentic, and a true driver of company growth. This funding allows us to continue building the operating system for support, where AI agents and CX team members are transformed into customer experts turning complex journeys into frictionless moments.”

“We are committed to partnering with companies who reimagine their industries in game-changing ways, and Quack’s product-led approach for proactive customer experience is exactly that,” said David Frankel, Partner at Hanaco Ventures. “Quack is unlocking companies’ capacity for hypergrowth by freeing them from dependence on limited and overwhelmed customer support infrastructure. Through their continued product development, they are redefining what it means to scale support and provide delightful experiences to customers, and we are excited to be part of their journey.”

“The best companies don’t just build products, they reset expectations for entire industries,” said Neil Grunberg, Co-Founder, Managing Partner at Storytime Capital. “At Storytime, we invest in companies shaping the future of work and technology that is redefining how support, collaboration, and service get done. The Quack team combines deep technical expertise with a clear vision for where customer experience needs to go and we are proud to back them as they scale their platform and set a new standard for support.”

Quack is already trusted by dozens of high-growth and global brands, including Artlist, Yotpo, WalkMe, and Hologram. The company will showcase its platform at the Customer Support Summit in San Francisco on September 16^th – 17^th. To learn more about Quack, click here.

About Quack

Quack is the only proactive agentic AI platform purpose-built for SaaS companies, transforming customer support from a reactive cost center into a growth engine. Quack enables CX teams to train, deploy, and manage unlimited AI agents that deliver instant, contextual, human-grade support across every channel, tailored to the pace and complexity of software companies. Quack unifies multi-channel interactions, knowledge management, QA, and Voice of Customer insights to provide every AI superpower support teams need within one CRM-agnostic operating system. Founded by Nadav Kemper and Aviram Roisman, Quack maintains a global presence in Tel Aviv, San Francisco, and New York. Visit www.quack.ai or follow us on LinkedIn for more information.

Contact info

Kate Schoenstadt
Headline Media
Email: [email protected]
Phone: +972 54 777 6684

SOURCE Quack

• Adopted across Fortune 500 employers, benefits partners, and insurers, Goodpath delivers integrative care for weight, MSK pain, sleep, diabetes, digestive health, and mental health in one platform
• Goodpath’s AI‑driven platform, guided by a world‑class medical team across 20+ specialties, personalizes care across conditions long managed in silos, delivering cost savings at scale and charting a path into the broader payer market
• With over 20% of eligible employees enrolling — five times the industry norm — Goodpath demonstrates that a virtual benefit can achieve the scale required to reduce claims costs in year one

BOSTON, Sept. 11, 2025 — Goodpath, the virtual provider of whole-person care for chronic conditions, today announced it has raised $18 million in Series A financing, led by MassMutual Ventures with participation from Healthy Ventures and current investors. Co-founded by CEO Bill Gianoukos and Dr. Akl Fahed, a cardiologist at Massachusetts General Hospital and faculty member at Harvard Medical School, Goodpath will use the new funding to accelerate the expansion of its AI‑driven, clinically‑validated care model. The platform delivers integrative care across weight management, musculoskeletal (MSK) pain, sleep, digestive health, mental health, diabetes, and cancer survivorship in one seamless experience.

Chronic condition care in the U.S. is highly fragmented beyond primary care. People with weight, MSK, digestive, mental health, or cancer needs often bounce between disconnected specialists and episodic treatments. This lack of coordination drives costs up: patients with the most fragmented care spend about $4,500 more each year and have worse outcomes. The bulk of the nation’s 90% of the nation’s $4.5 trillion healthcare bill is tied to chronic and mental health conditions. For self‑insured employers, that means higher claims, more disability leave, and growing frustration from employees about their health options.

At the core of Goodpath’s platform is a learning care model powered by an ever-growing real-world dataset. With more than 4.5 million real‑world data points drawn from member assessments, treatments, outcomes, and daily interactions, the platform captures how members actually experience care. That evidence fuels a dynamic care engine that learns directly from real‑world experience. As the dataset expands, the system evolves in step, improving recommendations, predicting outcomes with increasing precision, and tailoring pathways to each individual. This continuous feedback loop makes Goodpath’s approach more adaptive, more precise, and more effective with every member it serves.

“We believe every person should have access to care that’s not only high-quality, but intelligent. Care should adapt, evolve, and treat the whole person,” said Bill Gianoukos, CEO and Co-founder of Goodpath. “What was once a fragmented and costly system is now being reimagined through the power of AI. This funding enables us to continue building a smarter, more responsive healthcare model, one that brings personalized, effective care within reach for everyone.”

Unlike point solutions that address a single condition or care gap, Goodpath offers a new model: a virtual provider that treats multiple chronic conditions in a single pathway. Members receive personalized programs that combine medical expertise across more than 20 specialties with AI‑driven insights, unlimited 1:1 coaching, and practical tools delivered directly to their homes. By unifying care across the conditions that drive the majority of healthcare costs, Goodpath delivers the cost savings employers need and the health outcomes their workforces expect.

Goodpath delivers 15–20% enrollment across eligible populations, which is five times the industry average, and is backed by validated studies demonstrating reductions in total medical spend. In 2025, Goodpath will continue investing in outcome prediction models, AI-led personalization tools, and expanded product capabilities including prescribing, additional care pathways, and complex care navigation.

“Chronic and mental health conditions account for the vast majority of U.S. healthcare costs, and yet the way care is delivered has lagged behind. We believe the next generation of category leaders will be those that deliver this combination of scale, precision, and measurable cost impact in a single model,” said Eric Emmons, Managing Partner at MassMutual Ventures. “What excites us about Goodpath is that it is already demonstrating that combination: high engagement across large populations, predictive use of data and outcomes that show up directly in claims. That alignment of clinical credibility and financial impact points to how chronic care will be financed and delivered over the next decade.”

About Goodpath
Goodpath delivers whole-person care for chronic conditions, including weight management, MSK pain, diabetes, digestive health, sleep, mental health, and cancer survivorship. Through clinical care, dedicated coaching, and a multi-disciplinary care team, Goodpath helps members address both symptoms and underlying drivers of health, including nutrition, movement, sleep, and mental well-being. For more information, visit goodpath.com.

About MassMutual Ventures
MassMutual Ventures (MMV) is a multistage venture capital firm investing globally in enterprise SaaS, financial technology, climate technology, cybersecurity, and health technology companies. We help accelerate the growth of the companies we partner with by providing capital, connections, and expertise. With our deep operating network, MMV helps entrepreneurs build compelling and scalable companies of value. For more information, visit www.massmutualventures.com.

Media Contact
[email protected]

SOURCE Goodpath

ST. LOUIS, Sept. 11, 2025 — Interlock Equity (“Interlock”), a Los Angeles–based private equity firm, today announced a strategic growth investment in VeloSource (“the Company”), a leading provider of locum tenens staffing solutions. The partnership will accelerate VeloSource’s expansion, strengthen its specialty expertise, and advance its technology platform to better serve healthcare providers nationwide.

Founded in 2015 by Jeff Schaal and Patrick Donovan, VeloSource was built around a clear vision: connect healthcare organizations with the highest-quality physicians and advanced practitioners to ensure exceptional patient care. Today, the Company partners with hospitals, health systems, universities, and physician groups across the U.S., delivering top-tier staffing solutions that address critical workforce needs.

“Jeff and I are incredibly excited to join forces with Interlock Equity to bring outcome-driven Locum Tenens to the healthcare industry. Interlock offers key strategic support and client relationship synergy to rapidly foster growth in a competitive landscape.  As I transition to the Board, I have every confidence in Jeff and our team’s ability to achieve unparalleled excellence in the delivery of locum tenens solutions,” said Patrick Donovan, Founder/Partner at VeloSource.

“Partnering with Interlock represents an exciting new chapter for our company. Their commitment to innovation and long-term growth reflects our own values, and we look forward to what we can achieve together.  I’m thrilled about the opportunities this partnership provides to our team members as we further growth by fostering our unique culture and broadening our locum tenens solutions with a client-centric approach to the industry,” said Jeff Schaal, CEO and Founder at VeloSource.

“VeloSource is addressing one of the most urgent challenges in healthcare – bridging persistent provider shortages with highly qualified locum tenens professionals,” said Rob Zielinski, Managing Director at Interlock. “The Company is uniquely positioned to capture strong industry tailwinds, and we are excited to support Jeff, Patrick, and the entire VeloSource team in their next phase of growth while preserving the culture that has attracted top talent to the organization.”

Mike Orend, Managing Director at Interlock, added: “Jeff and Patrick have built an extraordinary company that stands out as a destination employer in the locum staffing industry. Their trusted client relationships, commitment to excellence, and people-first culture are exactly what we look for in a partner.”

About VeloSource

Recognized by Staffing Industry Analysts as a 2025 “Best Staffing Firm to Work For,” VeloSource is a premier healthcare staffing and recruitment agency specializing in locum tenens services. With a nationwide network of highly qualified providers, VeloSource delivers tailored workforce solutions that empower healthcare facilities to maintain continuity of care and achieve better patient outcomes.

About Interlock Equity

Founded in 2021 and headquartered in Los Angeles, Interlock Equity is a private equity firm dedicated to partnering with leadership teams of knowledge-based, people-driven businesses. Interlock invests in lower middle-market companies across North America, with a focus on mission-critical B2B and healthcare services. By providing strategic capital, deep industry expertise, and a collaborative approach, Interlock helps founders and management teams unlock transformative growth.

CONTACT:

Mike Gianas
VeloSource
(314) 297 – 0362
[email protected]

SOURCE VeloSource

SHANGHAI, Sept. 11, 2025 — YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech’s clinical programs and global strategic execution.

Dr. Yuxuan Wu, Founder and CEO of YolTech, “This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide.”

About YolTech Therapeutics
Founded in 2021, YolTech Therapeutics is advancing next-generation in vivo gene-editing therapies designed for one-time treatment. The company has built a fully integrated platform encompassing proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a cutting-edge lipid nanoparticle delivery system (Yol-LNPs), enabling precise, efficient, and tissue-specific gene editing across a broad range of therapeutic areas.

In 2024, YolTech’s lead program YOLT-201, a CRISPR-based therapy for transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in China to enter Phase I/IIa clinical trial. Since then, the company has advanced four clinical-stage programs addressing ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD).

YolTech operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up, ensuring manufacturing consistency and scalability across programs.

With one of the most extensive in vivo gene-editing clinical pipeline globally, YolTech continues to lead in the field. Its base-editing therapy YOLT-101, developed for familial hypercholesterolemia (HeFH), became the first in vivo base-editing program to receive IND clearance in both China and the United States.

SOURCE YolTech Therapeutics

Former chief data officer of UnitedHealthcare, Kaiser Permanente, and Optum launches new healthcare AI company to streamline workflows and reduce inefficiencies

PALO ALTO, Calif., Sept. 11, 2025 — Penguin Ai, a healthcare artificial intelligence company that solves administrative burdens, announced today that it has secured $29.7 million in venture funding, including a $25M Series A led by Greycroft. Other participants in the financing include UPMC Enterprises, SemperVirens, Snowflake Ventures, Watershed Ventures and Horizon Mutual Holdings, Inc, the parent of New Jersey’s largest and oldest health insurer. The round also included support from the original lead seed investors ManchesterStory and Overwater Ventures, as well as California Health Care Foundation, and Matt Kozlov, formerly of Techstars and now at Multiball Capital. Canvas Prime, Plug and Play and individual angels like John Santelli, former CIO of UnitedHealthcare and Eric Larsen, formerly of the Advisory Board also helped fund the company’s seed round last year. The funding will support hiring, product development, and scaling deployments with payers and providers.

Penguin Ai’s flagship platform is designed to help payers and providers streamline high-volume administrative workflows, significantly reduce operational costs, and improve overall efficiency through the use of advanced generative AI technologies.

“The healthcare industry is plagued by inefficiencies and is spending billions on administrative tasks annually,” said Fawad Butt, founder and CEO of Penguin Ai, and former chief data officer of UnitedHealthcare, Kaiser Permanente and Optum. “By harnessing the power of generative AI, we can significantly reduce these costs, improve accuracy, and unburden valuable resources so payers and providers can focus on delivering quality care to patients.”

Penguin Ai has already secured key partnerships with leading health plans, providers, and technology organizations and is actively collaborating with several customers to accelerate the development of its enterprise-grade AI platform, proprietary Language Models and Digital Workers and Agents.

“Since partnering with Penguin Ai over a year ago, we’ve been impressed with their bold platform vision and early customer traction,” said Mark Terbeek, partner at Greycroft. “We’re excited to see them accelerate their go-to-market initiatives and further advance their next-generation AI platform.”

From the inception of the company in early 2024, Penguin Ai has built a high-performing team while architecting an enterprise-grade AI platform. Penguin Ai’s leadership brings over 100 years of payer, provider and hi-tech experience from organizations like: Capital Blue Cross, UnitedHealthcare, Optum, Kaiser Permanente, Amazon, McKesson, Elevance, and federal health agencies.

Platform Over Point Solutions
A complete AI platform purpose-built for healthcare, Penguin Ai combines AI tooling with proprietary Language Models (LMs) and out-of-the box Digital Workers and Agents –all built specifically for back-office workflows. The platform enables customers to get their data ready for AI, use pre-built healthcare LLMs via APIs, or start with an out-of-the-box solution in areas such as medical coding, prior authorizations, claims adjudication, appeals management, risk adjustment, medical chart summarization or payment integrity, etc.

“At UPMC Enterprises, we innovate to solve real world problems in health care, which is a mindset shared by Penguin Ai and its founder, Fawad Butt,” said Nicholas Shapiro, vice president, UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. “Security and fairness, which have always been priorities in health care, are particularly crucial when incorporating AI into medical practice. Penguin Ai’s platform capabilities, specifically their comprehensive governance and bias correction, service those existing needs, while also preparing for future demands in this evolving AI market.”

“We invested in Penguin Ai because of its full-service healthcare platform vision and because the technology is fully AI native from the ground up and built by former executives from leading payer and provider organizations,” said Robby Peters, founder and managing partner at SemperVirens. “The company is entirely focused on automating complex and costly workflows within healthcare, and we believe their platform will benefit our LPs and strategic partners who want to leverage one solution rather than work with numerous vendors who offer AI-enhanced point solutions.” 

“Penguin Ai is redefining how healthcare payers and providers use data and AI to cut costs, reduce friction, and improve outcomes,” said Harsha Kapre, director of Snowflake Ventures. “Our investment brings their specialized applications directly into the Snowflake AI Data Cloud, giving healthcare organizations the confidence to embrace AI and transform their operations.”

Penguin Ai is poised to reduce administrative burdens across healthcare and currently serves health plans, providers and revenue cycle management companies as well as system integrators and technology partners to extend its reach and deliver joint solutions. To learn more or request a demo, visit www.penguinai.co.

About Penguin Ai
Penguin Ai is a healthcare AI company focused on transforming operations for healthcare payers and providers by leveraging cutting-edge generative AI technology. Its flagship platform combines task-specific Small Language Models (SLMs), Digital Workers and Agents, with a full-service healthcare AI platform to streamline healthcare administration processes such as prior authorizations, claims processing, medical records summarization, and appeals management. Designed to streamline healthcare workflows and enhance operational efficiency, Penguin Ai leverages advanced AI models, compliance capabilities, and Digital Workers and Agents to transform the way healthcare enterprises manage their data and operations. Founded by the former Chief Data Officer of Kaiser Permanente, UnitedHealthcare and Optum, Penguin Ai is on a mission to reduce the $1 trillion annual cost of healthcare administration inefficiencies. Through its cutting-edge AI solutions, Penguin Ai aims to streamline healthcare operations, lower costs, and enable better outcomes for patients and providers alike.

For more information about Penguin Ai and its transformative solutions, visit www.penguinai.co.

Media Contact:
Grace Vinton
Amendola Communications on behalf of Penguin Ai
(203) 561-8935
[email protected]

SOURCE Penguin Ai

PHOENIX, Sept. 11, 2025 — Trinity Capital Inc. (Nasdaq: TRIN) (the “Company”), a leading alternative asset manager, today announced the commitment of $26 million in growth capital to Unmind, the workplace mental health platform delivering complete care in one solution, powered by AI.

Unmind combines human expertise, digital innovation, and proven science so every employee can access the right support – from proactive and preventative AI guidance to therapy, coaching, crisis care, 24/7 programs, and wellbeing progress tracking. With tailored solutions for individuals, leaders, and organizations, Unmind helps build high-performing teams while driving productivity and growth for enterprises.

At the heart of their platform is Nova, Unmind’s mental health agent, which guides people to the right care at the right time while ensuring privacy and clinical oversight. Trusted by global brands, Unmind supports nearly 3 million employees worldwide.

“In today’s world, prioritizing mental health is vital, not just for individuals, but for the way we live and work together,” said Craig Fox, Managing Director of Tech Lending at Trinity Capital. “Unmind is transforming how people and businesses thrive, and we are proud to partner with a team so deeply committed to bringing wellbeing into the workplace.”

This new debt financing will help scale Unmind’s operations, further develop its proprietary AI agent “Nova,” attract talent, and invest in innovation. Trinity Capital’s $26 million funding, along with Unmind’s recent Series C and prior financings, brings the company’s total capital raised since inception to more than $100 million.

Dr. Nick Taylor, CEO and Co-Founder of Unmind, commented: “Workplace mental health has reached a turning point. Organizations now recognize they need solutions that support their people at every level – from proactive tools for individuals, to mental health training for leaders, to insights that shape whole-organization strategy. With Nova, our mental health agent at the center of the platform, we can guide every person to the right level of care while enabling businesses to build resilient, high-performing teams. Trinity’s support accelerates our work to deliver complete mental health care that drives both human and business potential.”

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $4.7 billion across over 420 investments since inception in 2008 (As of June 30, 2025). Headquartered in Phoenix, Arizona, Trinity Capital’s dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About Unmind
Unmind is a workplace mental health platform delivering complete care in one solution, powered by AI. It combines human expertise, digital innovation, and proven science so every person receives the right support – from proactive mental health tools, therapy, coaching, and crisis support, to AI guidance, 24/7 programs, and progress wellbeing tracking. At the heart of the platform is Nova, its AI-powered agent, guiding people to the right care at the right time while keeping data private and conversations clinically overseen. Trusted by global brands, Unmind supports nearly 3 million employees worldwide, including Uber, Disney, Major League Baseball, Standard Chartered, and Diageo.

For more information, visit [unmind.com](https://unmind.com/).

SOURCE Trinity Capital Inc.

SJF Ventures invests in AI-powered digital maternal health platform driving better patient outcomes and addressing the maternal mortality crisis

CUPERTINO, Calif., Sept. 10, 2025 — Lōvu Health, the digital maternal health platform ensuring care for mother and baby from conception through postpartum, announced the company secured $8 million in Series A funding, led by SJF Ventures with participation from Rogue Women’s Fund, Symphonic Capital, Emmeline Ventures, Magella Ventures, Oakwood Circle Ventures, Sand Hill Angels, Swizzle Ventures, Terrasys, Stand Together Ventures, and Alumni Ventures. In a nation where 49% of women forgo prenatal care, postnatal care, or both because of high costs and lack of access, Lōvu Health is reinventing maternal care with a new paradigm of continuous and connected wellness before and after birth.

In the United States, there are more than 3.6 million births per year. Despite spending about $126 billion on pregnancy and postpartum care, the nation ranks 64th in maternal mortality — the worst among high income countries. Over 80% of these deaths are preventable. To address this crisis, Lōvu supports the care plan chosen by each mother’s obstetrician with access to specialty care, real-time remote patient monitoring, and a personalized care journey.

“Our current one-size-fits-all maternal care model is failing moms and babies,” said Noel Pugh, co-founder and CEO at Lōvu Health. “Every expectant mother and her baby deserve equitable access to precision care guided by innovative technology and evidence-based insights. Lōvu’s AI-powered platform transforms workflows and modernizes clinical practices, helping clinicians closely monitor patients and intervene earlier when necessary, while offering wraparound support that changes the way we bring life into this world.”

Ensuring access to crucial maternal care is even more important in the wake of cuts to Medicaid and critical social safety net programs. With Lōvu’s unique business model, mothers receive 24/7 support as well as access to necessary specialty care and social support, while obstetricians create a net-new revenue stream at no additional cost or administrative burden. The platform is well placed to serve mothers regardless of whether they are uninsured or covered by Medicaid or commercial insurance.

Lōvu has a proven track record of improving access to care and outcomes for mothers and babies, especially in underserved populations. The platform, which often uncovers chronic conditions like hypertension or mental health concerns, provides urgently needed interventions for acute preeclampsia, substance use disorders and suicidal ideation. Overall, Lōvu delivered earlier identification and intervention for preeclampsia than would have been possible with a traditional care model for 6% of mothers, identified depression and anxiety in upwards of 30% of clinical populations, and among mothers on platform with chronic hypertension, 57% were identified due to being on Lōvu.

“The existing maternal care model in the United States leads to significant care gaps, especially because we do a poor job adequately identifying risk for pregnancies where additional care is needed,” said Dr. Santosh Pandipati, co-founder and Chief Health Officer at Lōvu Health. “Lōvu’s technology transforms the patient experience throughout pregnancy and postpartum. Every mother’s journey is tailored to her individual needs, and our care navigators and trusted marketplace ensure mothers can quickly access best-in-class services. We deliver actionable data for clinicians that drives prevention rather than crisis mitigation and results in improved outcomes for mother, baby, and family.”

Many clinicians are overworked and burning out (1 in 3 U.S. counties are maternal care deserts lacking local obstetricians), which leads to poor availability for patients and more costly emergency room visits. The crisis is exacerbated by the fact that applications to OB/GYN residencies have fallen in recent years and OBs are among the most sued physicians. Lōvu acts as an extension of the relationship between OBs and mothers, strengthening rather than replacing that crucial bond and significantly reducing the administrative burden for clinicians.

With Lōvu, fetal heart rate, maternal blood pressure, maternal weight, maternal heart rate, and mental health assessments are all captured in a dynamic dashboard that alerts clinicians to meaningful changes in health status. The platform connects patients to a curated marketplace of services and technologies, taking care of eligibility and verification to streamline the referral process. Clinicians reduce in-office visits while adding AI and evidence-based recommendations so they can confidently guide mothers to the best possible outcomes.

In addition to its core platform, Lōvu provides mothers with access to a curated, best-in-breed marketplace of more than 50 third-party digital vendors for specialty care needs that range from doula support, lactation support, sexual wellness counseling, pelvic floor, physical therapy, nutritional support, and mental health resources. The marketplace allows clinicians to optimize maternal outcomes and attract more patients to their practice, particularly in rural or lower income areas where clinicians may not otherwise be able to offer specialized care. Lōvu allows mothers to take charge of their care through their marketplace choices. The marketplace can also reduce the time it takes a mother to see a mental health provider by up to four months.

“SJF has had a long-standing interest in maternal health and Lōvu has stood out to us for years as we see the company’s care extension of the obstetrician’s office plus a novel marketplace of partnered specialty solutions as the optimal ‘win-win-win’ strategy for providers, health plans, and mothers,” said Perry Clarkson, Partner at SJF Ventures. “Pairing the company’s recent momentum with broader trends right now around increasingly alarming rates of maternal complications and mortality, we are proud to be partnering with Lōvu to drive critical change and impact to maternal care in this country.”

Lōvu will use the new funding to increase its investment in AI with the launch of three augmentative agents planned in the coming months. The funding will also support automation, integrations, and headcount as the company scales to meet demand from mothers, clinicians, and providers. The platform is optimizing the maternal care journey and addressing care gaps in an outdated model to help solve preventable maternal mortality across the country.

About Lōvu Health
Lōvu Health‘s digital wellness platform personalizes a mothers pregnancy journey from pre-conception through two years postpartum. The platform provides curated recommendations for maternal health services and patient monitoring technologies to support patients, inform clinicians, and reduce burdens on the healthcare system.

About SJF Ventures
Founded in 1999, SJF Ventures is an impact venture capital fund whose mission is to catalyze the development of highly successful businesses that drive lasting, positive changes. Its deep experience in healthcare includes portfolio companies mPulse, DUOS, and ChartSpan.

SOURCE Lōvu Health

Авторы из разных отраслей используют Replit для создания приложений, включая команды Zillow, Duolingo и Coinbase. Основываясь на этом импульсе роста клиентской базы, компания Replit запустила сегодня Agent 3, своего самого автономного агента на сегодняшний день. Эти достижения знаменуют собой переход от полезного агента к настоящему сотруднику. Agent 3 в десять раз более автономен, чем предыдущие версии, с возможностью тестирования и исправления кода, а также создания пользовательских агентов и рабочих процессов, которые могут автоматизировать сложные или повторяющиеся задачи для любого типа работы, а не только для разработки программного обеспечения.

«Мы первыми сделали вайб-кодинг реальностью для людей без опыта программирования по всему миру, — сказал Амджад Масад, генеральный директор и основатель Replit. —  С финансированием и нашим новым агентом по искусственному интеллекту мы можем повысить привлечение клиентов, чтобы стать стандартом для предприятий. Будущее захватывающее: миллионы, если не миллиарды людей воплощают свои идеи в жизнь с помощью нескольких кликов».

«Видение Replit — дать возможность каждому строить — нашло большой отклик у нас. Благодаря сотрудничеству с отдельными лицами, командами и предприятиями Replit стала ведущей агентской платформой искусственного интеллекта, создающей пользовательское программное обеспечение, агентов и рабочие процессы, — сказал Джей Парк (Jay Park), управляющий партнер и соучредитель Prysm Capital. — Мы очень рады поддержать команду Replit на следующем этапе их пути».

В дополнение к новым инвестициям компания Replit объявила, что ее продукты теперь доступны для глобальных клиентов через Google Cloud Marketplace. 

«Replit демонстрирует, что возможно с агентами ИИ, — сказал Джонатан Зильбер (Jonathan Silber), директор AI Futures Fund в Google. — Мы с нетерпением ждем совместной работы с ними для создания агентов с использованием Gemini, которые будут поддерживать предприятие и продолжать приносить преимущества Gemini разработчикам программного обеспечения».

Новые средства будут использованы для масштабирования операций, ускоренной разработки продуктов и глобальной экспансии, поскольку Replit создает новый способ работы в эпоху ИИ.

«Мы инвестировали в Replit, потому что считаем, что решения компании для вайб-кодинга способны изменить то, как строятся предприятия, предоставляя нетехническим сотрудникам инструменты для воплощения программных продуктов в жизнь, — сказал Кевин Вебер, вице-президент Amex Ventures. — Мы рады видеть, как технология Replit может ускорить разработку продуктов для предприятий любого размера и стимулировать рост компании».

Replit был начат с видения того, что каждый может создавать программное обеспечение. Разрушая барьеры между идеей и готовым продуктом, Replit дает возможность отдельным лицам, командам и предприятиям быстрее внедрять инновации и расширять сферу деятельности. 

Agent 3 — это прорыв в автономной разработке программного обеспечения.

• Agent 3 — это прорыв в автономной разработке программного обеспечения, где он может воплощать идеи в жизнь с минимальным вмешательством пользователя.
• Agent 3 — первый агент на рынке, который может работать как настоящий товарищ по команде. Agent 1 мог работать только 2 минуты, в то время как Agent 2 работал до 20 минут, и теперь Agent 3 может работать до 200 минут, решая задачи на уровне человека.
• Agent 3 может тестировать и исправлять свой код, постоянно улучшая приложение пользователя в фоновом режиме. Запатентованная тестовая система Replit в 3 раза быстрее и в 10 раз дешевле по сравнению с моделями компьютерного использования.
• Agent 3 чувствует себя настоящим разработчиком, где будет периодически решать тестировать себя. Пользователи смогут видеть браузер агента, когда он нажимает на приложение, проверяя кнопки, формы, API, источники данных и т. д., подтверждая, что каждая часть приложения работает должным образом.

Попробуйте Replit Agent 3 здесь.

О Replit

Replit — это платформа для создания агентского программного обеспечения, которая позволяет любому пользователю создавать приложения с использованием естественного языка. Имея миллионы пользователей по всему миру и более 500 000 профессиональных пользователей, Replit демократизирует разработку программного обеспечения, устраняя традиционные барьеры для создания приложений. Штаб-квартира компании находится в Сан-Франциско.

Контакты:
[email protected]

Видео — https://mma.prnewswire.com/media/2768855/Replit_Agent3_SeriesC_90_16x9_HD.mp4
Логотип — https://mma.prnewswire.com/media/2725892/Replit_Logo.jpg